The United States will temporarily allow compounding pharmacies to make six popular but unapproved peptides, including BPC-157 and TB-500, in a major shift in the country's peptides policy that opens a regulated route to substances long sold through a grey market. The Department of Health and Human Services (HHS) disclosed the interim policy on Wednesday, October 28, 2026, saying it will not take enforcement action against qualifying compounders while the Food and Drug Administration (FDA) considers a formal rule change. The decision does not approve any of the six peptides, and it does not make the compounded medicines FDA-approved drugs. It does, however, move them out of the shadows for patients who obtain them on a prescription, and it puts the Trump administration's wellness agenda at the centre of a sharp scientific and safety debate.
Under the interim policy, licensed compounding pharmacies and physicians may compound the six peptides for individual patients while regulators decide whether the substances should be formally added to the FDA's list of bulk drug substances that compounders are permitted to use. To qualify, compounders must certify the identity and purity of their ingredients, follow manufacturing standards, use proper labelling, report side effects and dispense only on a patient-specific prescription. Side-effect reporting was not previously mandated in this way, and HHS presented it as a safety gain over the unregulated market.
The six peptides covered are BPC-157, a tissue-repair compound often taken with TB-500 in a combination known online as the "Wolverine stack"; TB-500, promoted for healing and muscle recovery; Epitalon, promoted for sleep; KPV, promoted for wound healing and inflammatory conditions; MOTS-c, promoted for obesity and bone health; and Semax, promoted for migraines and chronic pain. All six were reviewed by the FDA's Pharmacy Compounding Advisory Committee in July 2026. The committee recommended that six of seven peptides it considered be added to the permitted compounding list, declining only emideltide. The interim policy follows that recommendation, even though FDA staff scientists had recommended against it.
HHS framed the move as a crackdown on the black market rather than a loosening of standards. "Under President Trump's leadership, HHS is working to put prevention and patient safety at the center of health care — and that includes confronting the risks of black-market peptides," spokesperson Emily Hilliard said. The department argued that the policy will discourage the widespread use of research-use-only peptides supplied by foreign manufacturers, which it said pose a safety risk to American patients, and improve patient access through domestic, licensed channels.
Peptides are short chains of amino acids, the building blocks of proteins. Some occur naturally in the body, where they trigger hormones needed for growth, metabolism and healing. Others are made in laboratories. Peptide-based medicines are already a pillar of modern medicine: insulin is a peptide, and so are GLP-1 weight-loss and diabetes drugs such as Wegovy and the experimental retatrutide from Eli Lilly. The difference, regulators stress, is that those medicines went through rigorous clinical trials and won FDA approval. The six peptides in the new policy have not.
Over the past year, peptides have boomed in popularity, driven by wellness influencers, fitness culture and celebrity endorsements, for uses ranging from anti-ageing and muscle recovery to tissue repair and longevity. Kennedy has said publicly that he uses peptides himself, with what he has described as really good effect, and the podcaster Joe Rogan is also reported to use them. During a recent interview, the plastic surgeon Ryan Neinstein said he prescribes them to patients. "These products have been used for years by consumers," Jeff Cohen, co-founder of the American Peptide Association, said this summer. "It only got into the public consciousness because of the GLP-1 issue, raising the bigger issue of peptides and exposing what had been going on for years, which is [when] consumers began to take responsibility for their own wellness."
The regulatory history is contested. In 2023, the FDA made it illegal to compound these peptides, citing safety concerns including contamination, allergic reactions and, in earlier agency assessments, possible tumour growth. A grey market filled the gap: retailers sold peptides labelled "for research use only", a workaround that let them claim the products were not meant for humans, even as buyers injected them. Earlier in 2026, Kennedy announced that advisers would assess 14 peptides and recommend whether they should be allowed to be compounded. Before the advisory committee's first meeting in July, the committee was restructured to include several experts with financial ties to the peptide business, according to MarketWatch. The advisers then voted in favour of reclassifying six of seven peptides, even though FDA staff recommended against doing so — a split that is rare but not unprecedented.
The interim policy then went to the White House Office of Management and Budget for review this month. That office took meetings with organisations including the Center for Science in the Public Interest, which has described peptides as a profound threat, and companies such as Hims & Hers Health, which plans to sell peptides. Shares in Hims & Hers rose 2.8 percent on Wednesday after the policy was issued, a sign of how quickly the market read the announcement as a commercial opening.
The most important thing to understand about the peptides policy is what it is not. It is not FDA approval. Enforcement discretion is a promise not to prosecute qualifying compounders for now; it does not declare the peptides safe, effective or lawful as approved drugs, and it does not add them to the formal 503A compounding list. A broader review of whether they should be formally reclassified is still under way, with the next FDA advisory meeting scheduled for February 2027.
What it does change is the practical risk for American compounders. Before Wednesday, a pharmacy that compounded BPC-157 or TB-500 risked FDA enforcement. Now, if it certifies ingredient identity and purity, follows manufacturing standards, labels properly, reports adverse events and works from patient-specific prescriptions, HHS says it will not act. State law still applies, including rules on who may prescribe, delegate and administer compounded medicines. The policy also creates a paper trail: adverse-event reports from licensed compounders will give regulators data they did not have from the grey market, where problems often went unreported.
For consumers, the change is subtler. A compounded peptide from a licensed pharmacy should, in theory, be purer and better labelled than a vial bought online as a research chemical. It will not, however, carry the assurance that comes with FDA approval, because the underlying substances still lack the clinical trials that approval requires. Much of the existing evidence comes from animal studies, and claims about recovery, anti-ageing or performance have not been established in robust human trials.
Critics reacted swiftly and bluntly. "Legally compounded arsenic is still arsenic," said Shabbir Safdar, executive director of the Partnership for Safe Medicines, which represents pharmaceutical and pharmacy interests. The group has filed a citizen petition asking the FDA to stop the compounding of certain peptides, arguing that it is illegal and poses safety risks. Dr Peter Lurie, a former FDA official who now leads the Center for Science in the Public Interest, said the FDA was essentially "turning a blind eye" to widen access to drugs that have not been proven to work.
Reports before the announcement described deeper unease inside the agency. Six people familiar with the policy's development told the Associated Press that most FDA scientific staff members opposed the effort, had limited input in drafting it and warned it could undermine the agency's mission of keeping unproven health products off the market. The people spoke on condition of anonymity to discuss confidential deliberations, and HHS did not immediately respond to that reporting.
Supporters argue the opposite: that regulation beats prohibition. Kennedy has argued that allowing access through 503A compounders gives consumers additional safety protections compared with buying from unregulated sellers, and HHS echoed that logic on Wednesday. The American Peptide Association and compounding advocates have long argued that patients were already using these substances, and that bringing production into licensed American pharmacies, with purity testing and adverse-event reporting, is safer than leaving the market to foreign research-chemical suppliers.
There is also a sporting dimension. BPC-157 and TB-500 are considered doping substances by international sports authorities, so athletes who use compounded versions risk anti-doping violations even when a pharmacy made the product legally. That distinction — legal to compound, banned in competition — is likely to confuse some buyers, and sports bodies may need to repeat their warnings in the coming weeks.
The peptides policy matters because it tests a central question in American health regulation: when millions of people are already using a substance, is it safer to regulate it or to ban it? The administration has chosen regulation, at least temporarily, and in doing so it has sided with a wellness movement led by its own health secretary over the caution of many of its own scientists. That tension will shape how the policy is judged, especially if adverse events emerge.
It also matters for the wider drug market. Compounding pharmacies sit in a special corner of US law: they may make medicines tailored to individual patients, but they are not drug manufacturers, and their products do not go through FDA approval. Expanding what they may compound, even temporarily, blurs the line between a personalised medicine and an unapproved drug sold at scale. If the six peptides are eventually added to the formal compounding list, the change could become permanent and could encourage applications for other peptides, including some of the original 14 that Kennedy's advisers assessed.
Finally, it matters for consumers right now. Anyone offered a compounded peptide should understand three facts: it is not FDA-approved, its benefits are unproven in rigorous human trials, and its risks — including contamination, allergic reaction and unknown long-term effects — are real even when the vial comes from a licensed pharmacy. A prescription does not turn an unproven substance into a proven one.
The next milestone is the FDA advisory meeting scheduled for February 2027, when advisers will revisit the evidence and the formal reclassification question. Before then, watch three things: whether compounders rush to offer the six peptides and how they price them; whether adverse-event reports reveal safety signals that force HHS to reconsider the interim policy, as it has said it may; and whether Congress, state regulators or sports authorities respond with their own rules or warnings. Hims & Hers and other telehealth companies are expected to move quickly, and their marketing claims will be closely watched by regulators and critics alike.
Patients considering a compounded peptide should talk to a doctor, ask what evidence supports it for their condition, check whether it could breach anti-doping or workplace rules, and be wary of any seller promising guaranteed healing, weight loss or anti-ageing effects. The policy has changed where these peptides may legally be made. It has not changed what science knows about them.
BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. They may now be compounded by qualifying pharmacies under HHS enforcement discretion, but none is FDA-approved.
No. The interim policy only means HHS will not take enforcement action against qualifying compounders for now. It is not FDA approval, and the peptides remain unapproved drugs.
HHS said the aim is to move patients away from black-market and research-use-only peptides supplied by foreign manufacturers and into licensed domestic pharmacies with purity, labelling and safety-reporting requirements.
Regulators and critics cite insufficient evidence of safety and effectiveness, plus risks of contamination, allergic reactions and unknown long-term effects. Much of the evidence comes from animal studies, not rigorous human trials.
A broader FDA review continues, with the next advisory meeting scheduled for February 2027. HHS may reconsider the interim policy if safety signals or quality problems emerge.
Related coverage: Miyoko's butter recall: plant-based spread pulled in 10 states over E. coli fears, ValuHealth acetaminophen recall: 100,134 bottles pulled over wrong label, Eye drops recall: 48 million cartons pulled nationwide.
Leave a Comment
| Today's Date:
